Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development
Miyoung Choi, Hyeon-Jeong Lee, Su-Yeon Yu, Jimin Kim, Jungeun Park, Seungeun Ryoo, Inho Kim, Dong Ah Park, Young Kyung Yoon, Joon-Sung Joh, Sunghoon Park, Ki Wook Yun, Chi-Hoon Choi, Jae-Seok Kim, Sue Shin, Hyun Kim, Kyungmin Huh, In-Seok Jeong, Soo-Han Choi, Sung Ho Hwang, Hyukmin Lee, Dong Keon Lee, MD Hwan Seok Yong, MD Ho Kee Yum
Journal of Korean Medical Science, doi:10.3346/jkms.2023.38.e195
Background: In Korea, during the early phase of the coronavirus disease 2019 (COVID-19) pandemic, we responded to the uncertainty of treatments under various conditions, consistently playing catch up with the speed of evidence updates. Therefore, there was high demand for national-level evidence-based clinical practice guidelines for clinicians in a timely manner. We developed evidence-based and updated living recommendations for clinicians through a transparent development process and multidisciplinary expert collaboration. Methods: The National Evidence-based Healthcare Collaborating Agency (NECA) and the Korean Academy of Medical Sciences (KAMS) collaborated to develop trustworthy Korean living guidelines. The NECA-supported methodological sections and 8 professional medical societies of the KAMS worked with clinical experts, and 31 clinicians were involved annually.
SUPPLEMENTARY MATERIALS Supplementary Table 1 COVID-19 severity classification system and definitions for adult patients Click here to view Supplementary Table 2 Korean COVID-19 severity classification system and definitions for adult patients
Click here to view
Supplementary Table 3 Coronavirus disease 2019 severity classification system and definitions for pediatric patients
Click here to view
Supplementary Table 4
Level of evidence and meaning based on Grading of Recommendations Assessment Development and Evaluation approach
Click here to view
Supplementary Table 5
Grade of recommendation based on the Grading of Recommendations Assessment Development and Evaluation approach Click here to view Supplementary Table 6 Summary of medication treatments recommendations (a total of 16 recommendations can be summarized as follows) Click here to view Supplementary Table 7 Summary of recommendations for respiratory critical care (a total of six clinical questions can be summarized as follows)
Click here to view
Supplementary Table 8 Summary of recommendations for pediatric care (a total of four clinical questions can be summarized as follows) Click here to view Supplementary Table 9 Summary of recommendation for emergency care (recommendation for one clinical question can be summarized as follows) Click here to view Supplementary Table 10 Summary of recommendations for diagnostic test (recommendation for one clinical question can be summarized as..
References
Cheyne, Navarro, Buttery, Chakraborty, Crane et al., Methods for living guidelines: early guidance based on practical experience. Paper 3: selecting and prioritising questions for living guidelines, J Clin Epidemiol
Cheyne, Navarro, Hill, Mcdonald, Tunnicliffe et al., Methods for living guidelines: early guidance based on practical experience, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2022.12.024Core, R: A Language and Environment for Statistical Computing
Guyatt, Oxman, Kunz, Atkins, Brozek et al., GRADE guidelines: 2. framing the question and deciding on important outcomes, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2010.09.012Hewitt, Mcdonald, Poole, White, Turner et al., Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence taskforce, J Clin Epidemiol
Higgins, Altman, Gøtzsche, Jüni, Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ,
doi:10.1136/bmj.d5928Hill, English, Campbell, Mcdonald, Pattuwage et al., Feasibility of national living guideline methods: The Australian Stroke Guidelines, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2021.11.020Kim, Park, Lee, Seo, Sheen et al., Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity, J Clin Epidemiol
Kim, Ryoo, Huh, Joo, Kim et al., Revised Korean Society of Infectious Diseases/ National Evidence-based Healthcarea Collaborating Agency guidelines on the treatment of patients with COVID-19, Infect Chemother,
doi:10.3947/ic.2021.0303Kim, Sung, Lee, Kim, Shin et al., Clinical performance of rapid and point-of-care antigen tests for SARS-CoV-2 variants of concern: a living systematic review and meta-analysis, Viruses,
doi:10.3390/v14071479Kowalski, Morgan, Falavigna, Florez, Etxeandia-Ikobaltzeta et al., Development of rapid guidelines: 1. systematic survey of current practices and methods, Health Res Policy Syst,
doi:10.1186/s12961-018-0327-8Lamontagne, Agarwal, Rochwerg, Siemieniuk, Agoritsas et al., A living WHO guideline on drugs for COVID-19, BMJ,
doi:10.1136/bmj.m3379Lamontagne, Stegemann, Agarwal, Agoritsas, Siemieniuk et al., A living WHO guideline on drugs to prevent covid-19, BMJ,
doi:10.1136/bmj.n526Lee, Kim, Choi, Choi, Joh et al., Early intubation and clinical outcomes in patients with severe COVID-19: a systematic review and meta-analysis, Eur J Med Res,
doi:10.1186/s40001-022-00841-6Lee, Kim, Choi, Choi, Joh et al., Efficacy and safety of prone position in COVID-19 patients with respiratory failure: a systematic review and meta-analysis, Eur J Med Res,
doi:10.1186/s40001-022-00953-zPottie, Smith, Matthews, Santesso, Magwood et al., A multistakeholder development process to prioritize and translate COVID-19 health recommendations for patients, caregivers and the public. A case study of the COVID-19 recommendation map, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2022.04.012Ryoo, Koh, Yu, Choi, Huh et al., Clinical efficacy and safety of interferon (type I and type III) therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, PLoS One,
doi:10.1371/journal.pone.0272826Yamakawa, Yamamoto, Terayama, Hashimoto, Ishihara et al., Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines, Acute Med Surg,
doi:10.1002/ams2.706Yamakawa, Yamamoto, Terayama, Hashimoto, Ishihara et al., Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines, Acute Med Surg,
doi:10.1002/ams2.789Yu, Koh, Choi, Ryoo, Huh et al., Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis, Emerg Microbes Infect
